Management of Chronic Hepatitis B in Patients from Special Populations

Lai, Ching–Lung; Yuen, Man‐Fung

doi:10.1101/cshperspect.a021527

Cited by 2 publications

(2 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This indicates that having cccDNA or pgRNA levels below detection limits may not signify complete "clearance" of these entities. This is similar to the situation of "HBsAg seroclearance", where HBsAg can still be detected in a substantial proportion of patients with more sensitive assays [22], and where severe, and even fatal, reactivations can occur with potent immune suppressors like rituximab [23]. At the time of the third biopsy, ihHBV DNA was still detectable in all patients, but was reduced by 99.84% to a low median level of 0.35 copies/cell.…”

Section: Discussionsupporting

confidence: 65%

Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B

Lai

Wong

et al. 2017

Journal of Hepatology

135

132

View full text Add to dashboard Cite

It is generally presumed that a form of hepatitis B virus DNA, called covalently closed circular DNA (cccDNA), which hides inside the nuclei of liver cells of patients with chronic hepatitis B, cannot be reduced by antiviral treatment. The present study showed that with prolonged treatment (median period 126months), cccDNA can be markedly reduced, with 49% of liver biopsies having undetectable cccDNA. This suggests that viral replication capacity would be very low after prolonged antiviral treatment.

show abstract

Section: Discussionsupporting

confidence: 65%

Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B

Lai

Wong

et al. 2017

Journal of Hepatology

135

132

View full text Add to dashboard Cite

show abstract

“…The treatment goals are to control HIV and HBV transmission, suppress viral replication and prevent drug resistance mutations in reverse transcriptase ( 4 ). The treatment duration for HBV in coinfected patients is indefinite due to the low response rates and the requirement for lifelong treatment for HIV ( 11 ). Thus, the drugs should be selected carefully and closely monitored during treatment to minimize the risk of HBV and HIV drug resistance.…”

Section: Introductionmentioning

confidence: 99%

Investigational drugs with dual activity against HBV and HIV (Review)

et al. 2020

View full text Add to dashboard Cite

Chronic hepatitis B (CHB) and acquired immunodeficiency syndrome (AIDS) are global public health problems that pose a significant health burden. Human immunodeficiency virus (HIV) and hepatitis B virus (HBV) coinfection is common, as these viruses have similar transmission routes, such as blood transmission, sexual transmission and mother-to-child transmission. Coinfection frequently leads to accelerated disease progression. For individuals coinfected with HIV/HBV, combination antiretroviral therapy containing dual anti-HBV drugs is recommended. Certain studies have also indicated the benefits of antiretroviral drugs with anti-HBV activity in patients with coinfection. A total of four Food and Drug Administration-approved HIV drugs also have anti-HBV activity; namely, emtricitabine, lamivudine, tenofovir disoproxil fumarate and tenofovir alafenamide, which are all nucleoside reverse transcriptase inhibitors. However, various issues, including drug resistance and side effects, limit their application. Therefore, it is necessary to develop more drugs with dual activity against HBV and HIV. The present review outlines the mechanisms, safety and efficacy of certain drugs that have been investigated for this purpose.

show abstract

Management of Chronic Hepatitis B in Patients from Special Populations

Cited by 2 publications

References 99 publications

Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B

Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B

Investigational drugs with dual activity against HBV and HIV (Review)

Contact Info

Product

Resources

About